Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 0.00 (0.00%)
Spread: 0.50 (0.029%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,733.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 1-European shares fall further as mounting trade fears hit cyclicals

Fri, 23rd Mar 2018 09:51

* STOXX hits lowest in 11 months, DAX above early March low

* Cyclicals lead sectoral losers, defensives outperform

* Precious metal miners lifted by safe haven demand(For a live blog on European stocks, type LIVE/ in an Eikonnews window)

By Danilo Masoni

MILAN, March 23 (Reuters) - European shares fell on Fridaywith autos and basic resources stocks bearing the brunt of awide sell-off triggered by mounting worries that U.S. tariffs onup to $60 billion of imports from China could escalate.

All sectors were trading in negative territory, sendingpan-regional STOXX 600 benchmark index falling for asecond day, down 1.4 percent to its lowest level since February2017.

All eyes were on the response from China, which urged theUnited States on Friday to "pull back from the brink", andunveiled its own plans to impose tariffs on up to $3 billion ofU.S. imports.

Although risks that the tariffs could trigger a full-blowntrade war, some investors said they still did not expect that tohappen, highlighting that the retaliation measures announced byChina remained relatively mild.

Caution, however, pushed investors into defensive stockslike utilities and telecoms, which declined byless than 1 percent but outperformed the broader market, as theyare seen as less exposed to a deterioration in global trade.

Euro zone indexes including the export-sensitive DAXalso fell more 1.8 percent but remained above earlyMarch lows, while the FTSE dropped 1.1 percent to fresh15-month lows reached on the back of a strengthening pound.

"Our central scenario remains one in which retaliation willbe contained and will leave little impact on growth, but therisk of it happening alone is enough for us to maintain apreference for defensive assets," said UniCredit economists ledby Chiara Silvestre in a note.

Enel fell 0.2 percent after Italy's biggestutility reported growth a 14.4 percent growth in its 2017ordinary net profit last year that to beat its own guidance.

Among the few gainers on Friday were shares in metal minersFresnillo, Randgold and Polymetal ,all up between 0.5 and 1.5 percent, as the gold price rose onthe back of growing demand for safe haven assets.

Still on the tariff front, the previously announced U.S.tariffs on steel and aluminium imports will take effect onFriday but more countries, including the European Union, haveobtained a temporary exemption.

"In theory it would be a soothing news but in reality itrisks making the confrontation between the U.S and Chinaharsher," said JCI Capital fund manager Alessandro Balsotti.

Among the companies, exposed to U.S. steel and aluminiumtariffs, shares in carmakers Fiat Chrysler and BMWfell 2.5 and 2.1 percent respectively, while steeltube maker Tenaris dropped 4.1 percent andThyssenKrupp declined 2.7 percent.

Elsewhere in corporate arena, Indivior plunged 4.4percent following an U.S. court ruling against the maker ofopioid addiction treatment Suboxone. Indivior said it intendedto appeal against the ruling in favour of generic competitorAlvogen.

Among the few gainers, GSK rose 2.9 percent after itpulled out of the bidding war for Pfizer's consumer healthbusiness <PFE.N,> following in the footsteps of ReckittBenckiser earlier this week.(Reporting by Danilo MasoniEditing by Alison Williams)

More News
17 Dec 2023 15:16

PRESS: GSK looks for deals in China as rebuilds relationship

(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.

Read more
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:24

GSK seeks to extend RSV vaccine approval in Japan

(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.

Read more
11 Dec 2023 08:28

GSK drug gets EU marketing backing for form of endometrial cancer

(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.

Read more
11 Dec 2023 07:41

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Read more
11 Dec 2023 07:23

GSK endometrial cancer treatment gets Europe authorisation

(Sharecast News) - GSK announced on Monday that the European Commission has granted marketing authorisation for 'Jemperli', or dostarlimab, in combination with chemotherapy for certain endometrial cancers.

Read more
7 Dec 2023 12:54

THG backer Kelso pushes for demerger to trim "inherent" valuation gap

(Alliance News) - THG PLC investor Kelso Group Holdings PLC on Thursday reiterated its call for a demerger, which the shareholder believes will help close the "disparity" between the e-commerce firm's share price and its true value.

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
27 Nov 2023 09:00

GSK announces positive results from Blenrep phase 3 blood cancer trial

(Alliance News) - GSK PLC on Monday said a phase 3 trial of belantamab mafodotin as a multiple myeloma treatment has produced positive headline results.

Read more
27 Nov 2023 08:02

GSK receives 'positive' headline results from phase III trial

(Sharecast News) - Drugmaker GSK announced on Monday that it had received positive headline results from a planned interim efficacy analysis from a phase III trial evaluating its elantamab mafodotin asset.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.